All Insurance articles – Page 12
-
OpinionHow to get your bulk annuity deal to the front of the insurer queue
When it comes to securing a bulk annuity deal preparation is everything, says Aon Hewitt’s Michael Walker.
-
OpinionEurope and pensions – where things are headed in the next three years
Matthew Connell from insurance company Zurich says not even pensions products can avoid the legislative pull of the European Union, whether the UK stays or goes.
-
Opinion
The cost of a buy-in: A trio of factors dominate pricing
Feature: Many more schemes are expected to explore derisking avenues such as buy-ins and buyouts in 2016, but whether to press ahead will come down to affordability, which hinges on at least three key factors.
-
Opinion
Indecision and fear: tax changes threaten the role of pensions in employee benefits
From the blog: More than half of schemes are considering offering a cash allowance to members affected by pension tax changes, as alterations to the lifetime allowance threaten to drive high-earners away from workplace pensions.
-
Opinion
Why the UK’s standing in the European pensions market is so important
Data Crunch: Spence Johnson’s Magnus Spence outlines why the UK’s place in European pensions is so significant, accounting for half of all assets held between Germany, the Netherlands and itself.
-
OpinionDerisking dead ends
Editorial: If you’re short of gift ideas for your favourite veteran trustee or scheme manager, the Pension Protection Fund’s Purple Book could be a good shout.
-
Opinion
How to take advantage of medically underwritten bulk annuities
Medically underwritten buyout prices are coming down, says Barnett Waddingham’s Gavin Markham, and it could be time for trustees to take advantage of them.
-
OpinionWhy the power of IGCs should not be underestimated
Investment governance committees lack the power of a trustee board, says Sackers’ Helen Ball, but they can still change workplace pensions for the better.
-
Opinion
Is the medically underwritten annuity market too good to be true?
Buyouts remain a popular derisking strategy for defined benefit schemes. Aon Hewitt’s Martin Bird looks at how the medically underwritten option is gaining ground in this burgeoning market.
-
NewsIORP amendment threatens pot-follows-member
A draft report from the European Parliament committee on economic and monetary affairs has threatened the possibility of pot-follows-member legislation being introduced, lawyers have warned.
-
News
Derisking market outpaces earlier estimates, topping £35bn
At £35bn, 2014's record derisking activity has exceeded initial estimates, a report has found, with experts also predicting a changing view of longevity will bring sustained market growth.
-
Opinion
Longevity risk: Is the 1000-year-old man (or woman) a member of your scheme?
Advances in biomedical sciences have dramatically increased lifespans, which poses a real risk to a lot of schemes, with many now looking at the best ways to reduce such a risk.
-
Opinion
Why buy-ins/buyouts are not always the right answer
Bulk annuity contracts such as buy-ins can actually increase a pension scheme’s overall risk, argues Mercer’s Andrew Ward, who looks at the alternatives to these deals in the latest Informed Comment.
-
Opinion
How to determine the value to your scheme of a buy-in/buyout contract
In this week’s Technical View, Premier’s Claire Plackett explains how schemes can assess whether buy-in and buyout quotations offer value.
-
Opinion
Why not all master trusts deserve the name
Now Pensions’ Morten Nilsson discusses the problems with insurer-backed master trusts, and how employers can stop themselves falling for false promises, in the latest edition of Informed Comment.
-
FeaturesBBC diversifies with insurance-linked securities
The broadcaster's scheme said its 1% allocation to ILSs provided “genuine diversification” to equities last year but the market remains limited.
-
Features
Why stalling on buyout could cost members
Schemes looking to derisk are facing fewer barriers and better value for their members, but they need to move fast, argues Long Acre Life’s David Norgrove.